SINCE 2014
Ruidi Biotech relies on its world-leading next-generation pulsed electric field ablation technology platform and hardware-software collaborative development capabilities. It has successively received support from more than ten National Natural Science Foundation projects and a number of major national science and technology programs. The company has also jointly established a provincial key laboratory for the medical transformation of pulsed electric field technology with the First Affiliated Hospital of Zhejiang University School of Medicine.
The company has applied for nearly 200 patents, with PCT patents targeting the European and American international markets, and has initiated CE certification for its products. Meanwhile, Ruidi Biotech has been recognized as a "Specialized, Sophisticated, Unique and New Small and Medium Enterprise in Zhejiang Province", a "Hangzhou Unicorn Potential Enterprise", a "Hangzhou Enterprise High-Tech R&D Center" and a "Hangzhou Doctor Innovation Station".
Hangzhou Ruidi Biotechnology Ltd. was founded in 2014 by scientists returning from the UK and the US. As a national high-tech enterprise, it focuses on the pulsed electric field energy platform and is committed to the innovation of high-end minimally invasive interventional medical devices, while promoting the biomedical translation and application of pulsed electric field technology.
Ruidi Biotech has currently developed a number of product pipelines covering oncology, atrial fibrillation, chronic encephalopathy and other fields, which have entered the special approval channel for innovative medical devices. Its production and R&D base is located in Haichuang Park, Future Sci-Tech City, Hangzhou. The company is equipped with Class 10,000 clean workshops designed in accordance with GMP standards, high-standard assembly workshops and complete testing laboratories, and has passed the ISO13485 quality management system certification.
History
Capacity
